BioAge Labs announces interim Phase 1 data for BGE-102

BioAge Labs (BIOA) announced positive interim data from the ongoing Phase 1 single ascending dose / multiple ascending dose clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients with cardiovascular risk factors. Key results: BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing; Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1beta, a cytokine directly downstream of NLRP3, at Day 14; High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid at Day 14; Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026